trial

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

NCTId NCT01749098
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 29 (actual)
Sponsored by Biogen
Primary completion 2014-02
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
29 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2012-12
Primary completion
2014-02
Eligibility
MALE · 21 Years · 45 Years

Interventions & indications

Drugs
PF-04958242Ketamine

Sponsors

BiogenLead Sponsor

Sites

2 total
New Haven, United StatesWest Haven, United States

Facts & assertions

4 sourced
Enrollment
29
Phase
PHASE1
Primary Completion Date
2014-02
Status
COMPLETED
relationships
The graph out of here
drug
PF-04958242
drug
Ketamine
drug
lead_sponsor
Biogen
company
indication
Schizophrenia
indication
Schizophrenia
indication